Mean body-weight change at 15 mg after 72 weeks in SURMOUNT-1 - a published trial result for the molecule, not a Form Labs product claim, and not for human use.
SURMOUNT-1 - New England Journal of Medicine, 2022Dual GIP + GLP-1 research reference
Tirzepatide
A dual-receptor peptide from large Phase 3 trials - the same molecule as the medicine Mounjaro. Supplied for laboratory research only, not for human use.
Tirzepatide is the same molecule as Mounjaro, the prescription diabetes and weight medicine. What we supply is not that medicine - it is the raw compound, freeze-dried, for laboratory research only. Here is what made researchers pay attention to it.
Current lot pricing
$99.00 AUD
Base vial price: $99.00 AUD
Vial size10 mg
Ships from Perth, Australia PostFree standard shipping over $250Plain, discreet packagingStore at 2-8 C
Supplied strictly as reference material for in-vitro laboratory research. Not a medicine, supplement, or food. Not for human or veterinary use.
Research use onlyWhy this molecule is studied
Why researchers study it.
When you eat, your gut sends chemical messages out to the rest of the body. Two of them are called GLP-1 and GIP. GLP-1 is the one that tells your brain you're full and slows your stomach down. GIP is more about how the body handles the sugar and fat from the meal that just arrived.
In the literature, semaglutide - Ozempic - acts on GLP-1 alone, and tirzepatide acts on both. That is why researchers nicknamed it a 'twincretin', and it is why the trials ran it head to head against semaglutide rather than against a sugar pill.
Those trials were enormous - SURPASS for type 2 diabetes, SURMOUNT for weight - and they are why this molecule is everywhere in the literature. But every one of those results belongs to the medicine, given to patients under medical supervision. None of them belong to the material on this page.
What is on this page is the molecule and the batch: what it is, how pure it is, and which lot you are getting. Form Labs does not sell Mounjaro, this is not a weight-loss product, and it is not for people or animals to take. It is reference material for laboratory research.
The research
What the published studies found.
HbA1c drop at 15 mg after 40 weeks in SURPASS-2, compared with semaglutide 1 mg - a published trial result for the molecule, not a Form Labs product claim, and not for human use.
SURPASS-2 - New England Journal of Medicine, 2021Receptor systems named in the Tirzepatide literature: GIP and GLP-1. This is why researchers describe it as a dual agonist or twincretin.
Published Tirzepatide researchAmino-acid peptide identity fact for LY3298176, developed by Eli Lilly. This is an identity detail, not an outcome claim.
Coskun et al., Molecular Metabolism, 2018Figures outside lot paperwork describe third-party research records for the molecule. They are not Form Labs product results or use claims.
Read the full research guideIdentity, papers, and research-use boundariesMechanism notes
Plain-language research labels.
Two signals. Here is what each one does, in plain terms - the published science on the molecule.
GLP-1
The 'that's enough' signal. Your gut releases it when food shows up; it tells your brain you are full and slows how quickly your stomach empties. This is the one - the only one - that Ozempic acts on.
GIP
The other gut signal, firing after the same meal. Its job leans towards insulin and what the body does with the sugar and fat that just turned up. This is the one Tirzepatide adds and semaglutide never touches.
Two at once
'Agonist' is just a word for a molecule that switches a receptor on. Tirzepatide switches on two. That is the whole story behind 'dual agonist' and 'twincretin', and behind trials that measured it against semaglutide, which switches on one. Retatrutide, for comparison, switches on three.
Order anchor
Form Laboratories
Tirzepatide with live bundle pricing.
- Independently tested for purity and identity, with the results shown on the lab report
- Batch TIRZ-2506 printed on the vial and matched to the account-delivered lab report
- Ships from Perth via Australia Post in plain, unbranded packaging, with tracking emailed
- 30-day purity guarantee: if an independent re-test comes back below the purity on the report, we refund the order in full
Base tier
$99.00 AUD
Single vial / 10 mg / $99.00 AUD per vial
Ships after order review. Reference material for research use only.
Testing documentation
Lot-level records
Australia-wide dispatch
Plain, tracked delivery
Plain fulfilment
Discreet outer packaging
Research use only
No human-use claims
COA proof
Batch paperwork before checkout.
98.3%
Measured purity is matched to the product record and batch paperwork.
Purity test (HPLC) at or above 98%Identity confirmedScreened for bacterial residue (endotoxin)
Certificate of AnalysisTIRZ-2506
CompoundTirzepatide
LotTIRZ-2506
Purity98.3%
Net peptide10 mg
AppearanceFreeze-dried reference material
ReleasedCurrent product record
Download COA summary
Build your stack
Study alongside other catalogue references.
These products are shown as catalogue pairings only. Add any line to the same cart for order review.
GHRH analog studied in growth-hormone-axis research
Tesamorelin
$249 AUD
Researchers can study this catalogue reference alongside Tirzepatide in the same order record.
Triple-receptor research peptide
Retatrutide
$149 AUD
Researchers can study this catalogue reference alongside Tirzepatide in the same order record.
Mitochondrial-derived peptide
MOTS-C
$99 AUD
Researchers can study this catalogue reference alongside Tirzepatide in the same order record.
FAQ
Questions, answered plainly.
TIRZ is supplied as laboratory research material only. It is 21+ only, not for human consumption, and not for veterinary use.
Yes. The product page lists lot, identity, purity, appearance, release status, and storage notes for TIRZ.
Follow the label and matching COA paperwork. This page repeats 2-8 C storage guidance and light-protection notes before checkout.
Tirzepatide is a lab-made peptide known in research as LY3298176, developed by Eli Lilly. Published studies describe it across GIP and GLP-1 receptor systems, which is why researchers call it a dual agonist or twincretin. Form Laboratories supplies it as research-use-only reference material, not as an approved medicine.
Tirzepatide is the same molecule used in Mounjaro and Zepbound. Mounjaro is TGA and FDA approved; Zepbound is FDA approved but not TGA-approved in Australia. The material described here is not those medicines, not a prescription product, and not for human or animal use.
SURPASS-2 reported a -2.30 point HbA1c change at 15 mg after 40 weeks, and SURMOUNT-1 reported -20.9% mean body-weight change at 15 mg after 72 weeks. Those figures are published medicine-trial results for the molecule, not Form Laboratories product claims.
No. Tirzepatide from Form Laboratories is for laboratory research only, 21+ only, not for human consumption, and not for veterinary use.
Yes - it's the same molecule. Mounjaro and Zepbound are the approved prescription medicines built on tirzepatide, sold by Eli Lilly. What Form Labs supplies is research-use-only reference material of the tirzepatide molecule - not those medicines, not a pharmacy or prescription product, and not for human or animal use. It's intended only for laboratory research.
The molecule is approved as a prescription medicine: by the FDA as Mounjaro (type 2 diabetes) and Zepbound (weight management), and by Australia's TGA as Mounjaro. Those are doctor-prescribed medicines. The material sold here is not an approved medicine - it's research-use-only reference material of the same molecule, supplied for laboratory research only.
The medicine Mounjaro is a prescription-only (Schedule 4) medicine in Australia, available through a doctor. Form Labs does not sell that medicine. What's on this page is reference material of the tirzepatide molecule for laboratory research use only - not for human use - and is supplied on that basis.
No. The published weight and blood-sugar results described here come from clinical trials of the medicine, not from anything Form Labs sells. This product is reference material for laboratory research only - it is not a medicine, not a weight-loss product, and not for people or animals to take.
Semaglutide (Ozempic/Wegovy) acts on one receptor system, GLP-1. Tirzepatide acts on two - GIP and GLP-1 - which is why researchers call it a dual agonist or 'twincretin'. Retatrutide adds a third, glucagon. All three are described here only as research molecules.
Add the size and quantity you want to your cart and check out. Instead of paying by card, you'll get an emailed invoice with our bank details - pay by bank transfer, quoting the reference. Once the payment clears we pack your order and send it, and you'll get a tracking email. A faster transfer (PayID or Osko) gets things moving sooner.
It ships from our base in Perth via Australia Post, in plain packaging with nothing identifying on the outside, once your payment has cleared. You'll get a tracking email, and the tracking link shows the delivery estimate for your address. On arrival, store it at 2-8 C and keep it out of light.
No. It's supplied strictly as reference material for laboratory research - not a medicine, supplement, or food, and not for people or animals to take. The research described on this page is about the tirzepatide molecule in published studies, not about a Form Labs product.
Form your biology
Tirzepatide, with the batch details visible.
Before you order, check batch TIRZ-2506 against the account-delivered lab report for that batch.
Added to cart